Human Insulin R / CD220 (28-944) Protein, His Tag (MALS & SPR verified)
分子别名(Synonym)
INSR,Insulin receptor,IR,CD220
表达区间及表达系统(Source)
Human Insulin R (28-944), His Tag (INR-H52Ha) is expressed from human 293 cells (HEK293). It contains AA His 28 - Lys 944 (Accession # P06213-2).
Predicted N-terminus: His 28
蛋白结构(Molecular Characterization)
![1.jpg 1.jpg](/SupplyImg1/2024-07-15/6385663733206290158572305.jpg)
This protein carries a polyhistidine tag at the C-terminus. The mature form of Insulin R a disulfide-linked heterotetramer composed of 2 alpha and 2 beta chains. Each α and β chain (partial fragment) has a calculated MW of 83.6 kDa and 22.8 kDa. The protein migrates as 120-130 kDa and 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
![2.jpg 2.jpg](/SupplyImg1/2024-07-15/6385663733961523432159328.jpg)
![3.jpg 3.jpg](/SupplyImg1/2024-07-15/6385663734304205207150992.jpg)
背景(Background)
胰岛素受体(INSR)也被称为CD抗原CD220,它可以被切割成以下两条链:胰岛素受体亚基α和胰岛素受体亚单位β。INSR是由2个α链和2个β链通过二硫键连接而成的四聚体。α链携带胰岛素结合区,而β链携带激酶结构域。与IGF1R形成杂交受体,该杂交体是由INSR的1条α链和1条β链以及IGF1R的1条a链和1个β链组成的四聚体。除了结合胰岛素外,胰岛素受体还可以结合胰岛素样生长因子(IGFI和IGFII)。INSR的Isoform Short对IGFII结合具有更高的亲和力。当存在于与IGF1R的杂交受体中时,INSR结合IGF1。
关键字: 胰岛素受体;Insulin R蛋白;CD220重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。